miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors

Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. Antagonizing miR-182 enhan...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Molecular cell Ročník 41; číslo 2; s. 210
Hlavní autoři: Moskwa, Patryk, Buffa, Francesca M, Pan, Yunfeng, Panchakshari, Rohit, Gottipati, Ponnari, Muschel, Ruth J, Beech, John, Kulshrestha, Ritu, Abdelmohsen, Kotb, Weinstock, David M, Gorospe, Myriam, Harris, Adrian L, Helleday, Thomas, Chowdhury, Dipanjan
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 21.01.2011
Témata:
ISSN:1097-4164, 1097-4164
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. Antagonizing miR-182 enhances BRCA1 protein levels and protects them from IR-induced cell death, while overexpressing miR-182 reduces BRCA1 protein, impairs homologous recombination-mediated repair, and render cells hypersensitive to IR. The impaired DNA repair phenotype induced by miR-182 overexpression can be fully rescued by overexpressing miR-182-insensitive BRCA1. Consistent with a BRCA1-deficiency phenotype, miR-182-overexpressing breast tumor cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1). Conversely, antagonizing miR-182 enhances BRCA1 levels and induces resistance to PARP1 inhibitor. Finally, a clinical-grade PARP1 inhibitor impacts outgrowth of miR-182-expressing tumors in animal models. Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy.
AbstractList Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. Antagonizing miR-182 enhances BRCA1 protein levels and protects them from IR-induced cell death, while overexpressing miR-182 reduces BRCA1 protein, impairs homologous recombination-mediated repair, and render cells hypersensitive to IR. The impaired DNA repair phenotype induced by miR-182 overexpression can be fully rescued by overexpressing miR-182-insensitive BRCA1. Consistent with a BRCA1-deficiency phenotype, miR-182-overexpressing breast tumor cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1). Conversely, antagonizing miR-182 enhances BRCA1 levels and induces resistance to PARP1 inhibitor. Finally, a clinical-grade PARP1 inhibitor impacts outgrowth of miR-182-expressing tumors in animal models. Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy.Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. Antagonizing miR-182 enhances BRCA1 protein levels and protects them from IR-induced cell death, while overexpressing miR-182 reduces BRCA1 protein, impairs homologous recombination-mediated repair, and render cells hypersensitive to IR. The impaired DNA repair phenotype induced by miR-182 overexpression can be fully rescued by overexpressing miR-182-insensitive BRCA1. Consistent with a BRCA1-deficiency phenotype, miR-182-overexpressing breast tumor cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1). Conversely, antagonizing miR-182 enhances BRCA1 levels and induces resistance to PARP1 inhibitor. Finally, a clinical-grade PARP1 inhibitor impacts outgrowth of miR-182-expressing tumors in animal models. Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy.
Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. Antagonizing miR-182 enhances BRCA1 protein levels and protects them from IR-induced cell death, while overexpressing miR-182 reduces BRCA1 protein, impairs homologous recombination-mediated repair, and render cells hypersensitive to IR. The impaired DNA repair phenotype induced by miR-182 overexpression can be fully rescued by overexpressing miR-182-insensitive BRCA1. Consistent with a BRCA1-deficiency phenotype, miR-182-overexpressing breast tumor cells are hypersensitive to inhibitors of poly (ADP-ribose) polymerase 1 (PARP1). Conversely, antagonizing miR-182 enhances BRCA1 levels and induces resistance to PARP1 inhibitor. Finally, a clinical-grade PARP1 inhibitor impacts outgrowth of miR-182-expressing tumors in animal models. Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy.
Author Beech, John
Gorospe, Myriam
Pan, Yunfeng
Helleday, Thomas
Harris, Adrian L
Weinstock, David M
Abdelmohsen, Kotb
Panchakshari, Rohit
Chowdhury, Dipanjan
Muschel, Ruth J
Kulshrestha, Ritu
Gottipati, Ponnari
Moskwa, Patryk
Buffa, Francesca M
Author_xml – sequence: 1
  givenname: Patryk
  surname: Moskwa
  fullname: Moskwa, Patryk
  organization: Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
– sequence: 2
  givenname: Francesca M
  surname: Buffa
  fullname: Buffa, Francesca M
– sequence: 3
  givenname: Yunfeng
  surname: Pan
  fullname: Pan, Yunfeng
– sequence: 4
  givenname: Rohit
  surname: Panchakshari
  fullname: Panchakshari, Rohit
– sequence: 5
  givenname: Ponnari
  surname: Gottipati
  fullname: Gottipati, Ponnari
– sequence: 6
  givenname: Ruth J
  surname: Muschel
  fullname: Muschel, Ruth J
– sequence: 7
  givenname: John
  surname: Beech
  fullname: Beech, John
– sequence: 8
  givenname: Ritu
  surname: Kulshrestha
  fullname: Kulshrestha, Ritu
– sequence: 9
  givenname: Kotb
  surname: Abdelmohsen
  fullname: Abdelmohsen, Kotb
– sequence: 10
  givenname: David M
  surname: Weinstock
  fullname: Weinstock, David M
– sequence: 11
  givenname: Myriam
  surname: Gorospe
  fullname: Gorospe, Myriam
– sequence: 12
  givenname: Adrian L
  surname: Harris
  fullname: Harris, Adrian L
– sequence: 13
  givenname: Thomas
  surname: Helleday
  fullname: Helleday, Thomas
– sequence: 14
  givenname: Dipanjan
  surname: Chowdhury
  fullname: Chowdhury, Dipanjan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21195000$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LxDAYhIOsuB_6D0Ry89SaN22a9FjXTxBdFr1a0ibVLG1Sm1TZf--KK3iaYXgYmJmjiXVWI3QKJAYC2cUm7lxb6zam5CeiMSHsAM2A5DxKIUsn__wUzb3fEAIpE_kRmlKAnBFCZui1M-sIBI06rYwMWmHlvuyg38ZWBuMsdg2-XC8LwKbrZR08vnos8KB7aQYsrcJeW2-C-TRhi4PDq2K9wsa-m8oEN_hjdNjI1uuTvS7Qy8318_Iueni6vV8WD1HNchGiKs8kqZKE1GmmqcoblhCdZBWjOYckY00jIa0l11wJnjBQKUhGBEBaKQ6NoAt0_tvbD-5j1D6UnfG7c1pptRt9KVJOBWSE78izPTlWu81lP5hODtvy7xL6DQeZZRA
CitedBy_id crossref_primary_10_1007_s10059_012_0118_y
crossref_primary_10_1186_s12957_022_02851_4
crossref_primary_10_1038_s41375_018_0238_2
crossref_primary_10_3390_genes9090427
crossref_primary_10_1093_biolre_ioy183
crossref_primary_10_1016_j_currproblcancer_2018_01_001
crossref_primary_10_1016_j_phrs_2015_04_015
crossref_primary_10_1002_gcc_22221
crossref_primary_10_1111_cas_14599
crossref_primary_10_1093_abbs_gmu003
crossref_primary_10_1038_jhg_2016_89
crossref_primary_10_4161_cc_23051
crossref_primary_10_1186_s13045_020_0844_0
crossref_primary_10_3389_fgene_2015_00242
crossref_primary_10_1038_s41598_017_01185_6
crossref_primary_10_1007_s00018_011_0875_3
crossref_primary_10_1038_onc_2012_131
crossref_primary_10_1016_j_ijbiomac_2025_146386
crossref_primary_10_1002_med_21442
crossref_primary_10_4049_jimmunol_1402261
crossref_primary_10_1038_onc_2017_187
crossref_primary_10_3390_biomedicines10020199
crossref_primary_10_1016_j_tcb_2013_09_008
crossref_primary_10_1186_s12885_022_09761_4
crossref_primary_10_1038_onc_2013_65
crossref_primary_10_3390_ijms26010127
crossref_primary_10_1038_nrn4020
crossref_primary_10_1007_s12013_014_0244_6
crossref_primary_10_1038_s42003_022_03714_0
crossref_primary_10_1093_carcin_bgu322
crossref_primary_10_1089_ars_2013_5718
crossref_primary_10_3892_ijmm_2017_2905
crossref_primary_10_1038_s41374_018_0169_6
crossref_primary_10_1007_s11912_018_0709_7
crossref_primary_10_3390_ijms231911856
crossref_primary_10_3390_cancers12071838
crossref_primary_10_3390_ijms131114898
crossref_primary_10_1007_s00401_012_0969_5
crossref_primary_10_1016_j_febslet_2013_05_006
crossref_primary_10_1038_nrc3185
crossref_primary_10_1186_gb_2014_15_3_r51
crossref_primary_10_1016_j_senol_2024_100658
crossref_primary_10_3390_ijms20225527
crossref_primary_10_1158_1078_0432_CCR_18_1346
crossref_primary_10_1186_s13046_019_1490_7
crossref_primary_10_1002_mrd_23255
crossref_primary_10_1016_j_molcel_2016_02_001
crossref_primary_10_1038_emboj_2012_86
crossref_primary_10_1042_EBC20200008
crossref_primary_10_1038_s41598_017_07979_y
crossref_primary_10_1093_nar_gkr843
crossref_primary_10_1146_annurev_neuro_062012_170309
crossref_primary_10_4161_cc_10_8_15273
crossref_primary_10_1016_j_febslet_2015_05_030
crossref_primary_10_1016_j_semcancer_2023_11_009
crossref_primary_10_1093_jrr_rrt014
crossref_primary_10_3390_cells11091509
crossref_primary_10_1159_000371507
crossref_primary_10_1007_s11033_018_4358_6
crossref_primary_10_3390_cancers15041346
crossref_primary_10_1016_j_trsl_2012_01_022
crossref_primary_10_1186_s13045_022_01360_x
crossref_primary_10_1002_cam4_70986
crossref_primary_10_1038_bjc_2015_6
crossref_primary_10_1155_2014_820248
crossref_primary_10_3892_or_2014_3246
crossref_primary_10_1016_j_dnarep_2012_10_007
crossref_primary_10_3390_diagnostics10050298
crossref_primary_10_3892_ijo_2012_1531
crossref_primary_10_3389_fonc_2014_00133
crossref_primary_10_1016_j_dnarep_2015_04_017
crossref_primary_10_1371_journal_pone_0153113
crossref_primary_10_1002_biot_201100143
crossref_primary_10_1016_j_cryobiol_2017_04_013
crossref_primary_10_1093_annonc_mdt306
crossref_primary_10_1007_s12017_013_8239_9
crossref_primary_10_1111_jcmm_16007
crossref_primary_10_3390_cancers12113298
crossref_primary_10_1007_s00204_016_1668_0
crossref_primary_10_3389_fgene_2015_00320
crossref_primary_10_1007_s12032_014_0255_6
crossref_primary_10_1186_2052_8426_2_16
crossref_primary_10_1038_cddis_2016_246
crossref_primary_10_1093_nar_gkv691
crossref_primary_10_3390_cancers10120487
crossref_primary_10_1186_1746_1596_9_143
crossref_primary_10_1007_s10555_021_09992_0
crossref_primary_10_1080_15257770_2019_1704778
crossref_primary_10_3892_or_2017_5411
crossref_primary_10_1155_2021_3408937
crossref_primary_10_3390_ijms15046314
crossref_primary_10_1158_1078_0432_CCR_15_1063
crossref_primary_10_1016_j_dnarep_2016_09_003
crossref_primary_10_3389_fonc_2019_00799
crossref_primary_10_1016_j_canlet_2018_01_014
crossref_primary_10_1016_j_biopha_2017_08_144
crossref_primary_10_1016_j_bbadis_2014_12_001
crossref_primary_10_1007_s13277_015_4297_y
crossref_primary_10_1038_s41568_022_00518_6
crossref_primary_10_1038_srep31651
crossref_primary_10_3892_mmr_2018_9268
crossref_primary_10_1134_S1022795417020077
crossref_primary_10_3390_cancers12061662
crossref_primary_10_3389_fonc_2018_00352
crossref_primary_10_1186_bcr3682
crossref_primary_10_1016_j_clon_2015_07_004
crossref_primary_10_1016_S2221_1691_11_60042_7
crossref_primary_10_3390_ijms150814475
crossref_primary_10_1093_neuonc_nos089
crossref_primary_10_1158_1541_7786_MCR_13_0292
crossref_primary_10_1016_j_pbiomolbio_2020_12_005
crossref_primary_10_1016_j_archoralbio_2016_09_012
crossref_primary_10_1016_j_critrevonc_2017_04_006
crossref_primary_10_1158_0008_5472_CAN_14_1041
crossref_primary_10_1016_j_molmed_2014_07_004
crossref_primary_10_1016_j_genrep_2022_101565
crossref_primary_10_3389_fvets_2025_1637277
crossref_primary_10_1016_j_exphem_2016_07_007
crossref_primary_10_1186_s12885_019_6017_2
crossref_primary_10_1158_0008_5472_CAN_13_1841
crossref_primary_10_1016_j_ccr_2011_01_047
crossref_primary_10_1007_s10561_019_09797_0
crossref_primary_10_5306_wjco_v5_i4_730
crossref_primary_10_1038_modpathol_2012_118
crossref_primary_10_1210_er_2012_1045
crossref_primary_10_1186_s12885_017_3453_8
crossref_primary_10_3389_fonc_2019_00210
crossref_primary_10_3390_cells9040874
crossref_primary_10_1186_s13053_017_0076_7
crossref_primary_10_4049_jimmunol_1800071
crossref_primary_10_1158_1541_7786_MCR_12_0649
crossref_primary_10_3389_fgene_2022_920390
crossref_primary_10_1016_j_gde_2013_01_002
crossref_primary_10_1007_s00109_018_1682_1
crossref_primary_10_3390_molecules23112789
crossref_primary_10_1007_s12185_017_2300_7
crossref_primary_10_1109_TNB_2016_2539365
crossref_primary_10_1016_j_canlet_2015_12_026
crossref_primary_10_1186_1471_2407_14_138
crossref_primary_10_1016_j_ijheh_2018_07_003
crossref_primary_10_1016_j_clbc_2023_05_012
crossref_primary_10_1016_j_semcancer_2022_02_001
crossref_primary_10_1101_gad_225045_113
crossref_primary_10_3892_ol_2019_10169
crossref_primary_10_1016_j_tox_2014_05_003
crossref_primary_10_3109_10428194_2012_693178
crossref_primary_10_1007_s10522_020_09862_2
crossref_primary_10_1038_nrm3523
crossref_primary_10_1371_journal_pone_0108066
crossref_primary_10_1016_j_drup_2013_05_001
crossref_primary_10_1074_jbc_M113_475657
crossref_primary_10_1016_j_dnarep_2021_103125
crossref_primary_10_1111_iju_15043
crossref_primary_10_1159_000540863
crossref_primary_10_1172_JCI62339
crossref_primary_10_1002_ijc_30574
crossref_primary_10_1016_j_molonc_2011_07_001
crossref_primary_10_1016_j_pbiomolbio_2015_05_004
crossref_primary_10_3390_ijms19092741
crossref_primary_10_1080_21691401_2019_1638791
crossref_primary_10_1016_j_arr_2023_102137
crossref_primary_10_1038_srep06495
crossref_primary_10_1038_s41467_023_38925_4
crossref_primary_10_3389_fcell_2020_00680
crossref_primary_10_1016_j_ijbiomac_2025_144360
crossref_primary_10_1038_cddis_2013_227
crossref_primary_10_1016_j_canlet_2019_06_015
crossref_primary_10_1186_s12935_023_02972_0
crossref_primary_10_1093_nar_gkv703
crossref_primary_10_1177_17590914221101704
crossref_primary_10_1038_s12276_021_00557_3
crossref_primary_10_1007_s11684_012_0188_4
crossref_primary_10_1002_wrna_1571
crossref_primary_10_1002_path_4000
crossref_primary_10_1111_gtc_12100
crossref_primary_10_3390_ijms232314672
crossref_primary_10_1007_s13402_017_0341_9
crossref_primary_10_1186_1471_2164_14_731
crossref_primary_10_1007_s10815_015_0585_0
crossref_primary_10_1016_j_mrfmmm_2011_03_012
crossref_primary_10_1073_pnas_2114006119
crossref_primary_10_1002_jcb_29844
crossref_primary_10_3892_or_2015_3833
crossref_primary_10_3390_ijms17122087
crossref_primary_10_1016_j_gene_2018_11_011
crossref_primary_10_1016_j_trsl_2018_06_001
crossref_primary_10_1158_0008_5472_CAN_12_0103
crossref_primary_10_1186_s12916_025_04247_z
crossref_primary_10_1007_s12210_013_0263_z
crossref_primary_10_1016_j_critrevonc_2018_01_008
crossref_primary_10_1245_s10434_012_2467_3
crossref_primary_10_1016_j_tox_2020_152441
crossref_primary_10_1038_s41598_017_12259_w
crossref_primary_10_7554_eLife_02445
crossref_primary_10_1007_s00401_011_0924_x
crossref_primary_10_1016_j_ijrobp_2013_12_036
crossref_primary_10_4161_15384101_2014_958413
crossref_primary_10_3390_molecules19045379
crossref_primary_10_1155_2016_2346585
crossref_primary_10_1002_jcb_24488
crossref_primary_10_1016_j_mce_2017_02_009
crossref_primary_10_1158_0008_5472_CAN_14_2783
crossref_primary_10_1007_s12094_012_0877_0
crossref_primary_10_1038_cddis_2017_116
crossref_primary_10_1038_s43856_025_00791_0
crossref_primary_10_1007_s13402_015_0239_3
crossref_primary_10_1007_s00018_012_0959_8
crossref_primary_10_1111_1759_7714_12164
crossref_primary_10_1210_en_2013_1929
crossref_primary_10_3892_ol_2013_1593
crossref_primary_10_3389_fmolb_2021_655786
crossref_primary_10_1016_j_ygyno_2017_10_003
crossref_primary_10_1002_ijc_27632
crossref_primary_10_1186_s13578_020_00390_7
crossref_primary_10_1186_1479_5876_12_109
crossref_primary_10_1667_RR14370_1
crossref_primary_10_3389_fphar_2023_1258387
crossref_primary_10_1158_0008_5472_CAN_13_3157
crossref_primary_10_1371_journal_pone_0216400
crossref_primary_10_1002_cbf_2847
crossref_primary_10_1080_01635581_2021_1936082
crossref_primary_10_3390_ijms23063231
crossref_primary_10_1007_s12035_019_01717_3
crossref_primary_10_1002_pros_22626
crossref_primary_10_3390_ijms21113850
crossref_primary_10_1002_humu_22159
crossref_primary_10_1080_10408363_2017_1313190
crossref_primary_10_3389_fonc_2023_1155254
crossref_primary_10_3390_cancers17183011
crossref_primary_10_1074_jbc_M112_410951
crossref_primary_10_1007_s10911_011_9204_6
crossref_primary_10_1007_s10549_022_06533_3
crossref_primary_10_1002_mc_22286
crossref_primary_10_1186_s12885_021_08863_9
crossref_primary_10_1080_15384101_2015_1014147
crossref_primary_10_1016_j_hoc_2018_07_006
crossref_primary_10_1016_j_jconrel_2021_01_014
crossref_primary_10_1016_j_bbagen_2013_01_009
crossref_primary_10_1016_j_dnarep_2013_02_003
crossref_primary_10_3389_fgene_2021_683809
crossref_primary_10_1093_abbs_gmw105
crossref_primary_10_1134_S1022795414080092
crossref_primary_10_1172_JCI66058
crossref_primary_10_1158_0008_5472_CAN_18_3190
crossref_primary_10_1158_2159_8290_CD_15_0714
crossref_primary_10_1038_nature10760
crossref_primary_10_1186_s12916_015_0425_1
crossref_primary_10_1186_s13045_017_0466_3
crossref_primary_10_1177_1010428317695525
crossref_primary_10_3389_fonc_2020_01415
crossref_primary_10_1016_j_bbcan_2020_188413
crossref_primary_10_3389_fgene_2020_00809
crossref_primary_10_1074_jbc_M111_262915
crossref_primary_10_1093_nar_gkr149
crossref_primary_10_1038_cdd_2011_190
crossref_primary_10_3390_ijms242116010
crossref_primary_10_3390_computation9120146
crossref_primary_10_1007_s10911_021_09478_3
crossref_primary_10_1007_s11033_022_07234_2
crossref_primary_10_1016_j_canlet_2014_07_026
crossref_primary_10_1073_pnas_1402604111
crossref_primary_10_1007_s13277_014_2025_7
crossref_primary_10_1097_ALN_0000000000001588
crossref_primary_10_3390_jcm8040435
crossref_primary_10_1016_j_fsi_2019_07_063
crossref_primary_10_1038_ncomms13884
crossref_primary_10_1089_ars_2013_5514
crossref_primary_10_1016_j_molcel_2011_01_005
crossref_primary_10_1242_jcs_258601
crossref_primary_10_1172_JCI90825
crossref_primary_10_4161_cc_24757
crossref_primary_10_1038_onc_2013_48
crossref_primary_10_1186_s12885_019_5798_7
crossref_primary_10_1261_rna_034926_112
crossref_primary_10_3390_cells9010029
crossref_primary_10_1007_s10549_018_4850_7
crossref_primary_10_3390_ijms23010096
crossref_primary_10_3892_ol_2017_6778
crossref_primary_10_1016_j_abb_2016_02_018
crossref_primary_10_1158_1078_0432_CCR_16_0247
crossref_primary_10_1016_j_tibs_2011_06_002
crossref_primary_10_1016_j_tips_2011_10_001
crossref_primary_10_3390_cancers13112690
crossref_primary_10_1186_s12943_024_01967_3
crossref_primary_10_3389_fonc_2021_700853
crossref_primary_10_1002_ijc_30849
crossref_primary_10_1007_s00109_013_1055_8
crossref_primary_10_3390_biomedicines10061219
crossref_primary_10_1038_s41467_018_07657_1
crossref_primary_10_1517_14728222_2014_882900
crossref_primary_10_1007_s10549_012_2169_3
crossref_primary_10_1016_j_apsb_2016_09_002
crossref_primary_10_1016_j_tox_2018_05_009
crossref_primary_10_1158_1541_7786_MCR_14_0201
crossref_primary_10_1186_s40364_024_00653_2
crossref_primary_10_1186_s12885_016_2261_x
crossref_primary_10_2119_molmed_2010_00240
crossref_primary_10_3389_fonc_2021_770103
ContentType Journal Article
Copyright Copyright © 2011 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2011 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.molcel.2010.12.005
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
EISSN 1097-4164
ExternalDocumentID 21195000
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Cancer Research UK
  grantid: 11563
– fundername: NCI NIH HHS
  grantid: R01 CA142698
– fundername: Medical Research Council
  grantid: G0700730
– fundername: NCI NIH HHS
  grantid: R01CA142698
GroupedDBID ---
--K
-DZ
-~X
0R~
123
1~5
2WC
4.4
457
4G.
5RE
62-
7-5
AAEDT
AAEDW
AAHBH
AAIKJ
AAKRW
AAKUH
AALRI
AAMRU
AAVLU
AAXUO
AAYWO
ABDGV
ABJNI
ABMAC
ACGFO
ACGFS
ACNCT
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEFWE
AENEX
AEUPX
AEXQZ
AFFNX
AFPUW
AFTJW
AGCQF
AGHFR
AGKMS
AIGII
AITUG
AKAPO
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EFKBS
EIF
EJD
F5P
FCP
FDB
FEDTE
FIRID
HH5
HVGLF
HZ~
IH2
IHE
IXB
J1W
JIG
KQ8
L7B
M3Z
M41
N9A
NPM
O-L
O9-
OK1
P2P
RIG
ROL
RPZ
SDG
SES
SSZ
TR2
5VS
7X8
ID FETCH-LOGICAL-c598t-b96a0b330c46e2d9f530e36b52971365ffa14ca7e7d87351d41a508114bd71f82
IEDL.DBID 7X8
ISICitedReferencesCount 369
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000286708300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1097-4164
IngestDate Sun Nov 09 05:01:36 EST 2025
Mon Jul 21 06:06:55 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright © 2011 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c598t-b96a0b330c46e2d9f530e36b52971365ffa14ca7e7d87351d41a508114bd71f82
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://dx.doi.org/10.1016/j.molcel.2010.12.005
PMID 21195000
PQID 847281607
PQPubID 23479
ParticipantIDs proquest_miscellaneous_847281607
pubmed_primary_21195000
PublicationCentury 2000
PublicationDate 2011-01-21
PublicationDateYYYYMMDD 2011-01-21
PublicationDate_xml – month: 01
  year: 2011
  text: 2011-01-21
  day: 21
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular cell
PublicationTitleAlternate Mol Cell
PublicationYear 2011
References 21255724 - Mol Cell. 2011 Jan 21;41(2):135-7. doi: 10.1016/j.molcel.2011.01.005.
Mol Cell. 2014 Jan 9;53(1):162-3
References_xml – reference: - Mol Cell. 2014 Jan 9;53(1):162-3
– reference: 21255724 - Mol Cell. 2011 Jan 21;41(2):135-7. doi: 10.1016/j.molcel.2011.01.005.
SSID ssj0014589
Score 2.5263042
Snippet Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here we show that BRCA1...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 210
SubjectTerms Animals
Antineoplastic Agents - pharmacology
BRCA1 Protein - genetics
Cell Differentiation
Cell Line, Tumor
DNA Breaks, Double-Stranded - radiation effects
DNA Repair - drug effects
Down-Regulation
Humans
K562 Cells
Mice
MicroRNAs - genetics
MicroRNAs - metabolism
MicroRNAs - physiology
Phthalazines - pharmacology
Piperazines - pharmacology
Poly (ADP-Ribose) Polymerase-1
Poly(ADP-ribose) Polymerase Inhibitors
Title miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors
URI https://www.ncbi.nlm.nih.gov/pubmed/21195000
https://www.proquest.com/docview/847281607
Volume 41
WOSCitedRecordID wos000286708300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA4-wYvv94McvAabNG2Sk6wvvLgsi8KeXJJOggVtdbsK_nuTpqsn8eClt0KZTGe-mfkmH0KnuVDgExEQSLUiXBpLlAQgDBxzFowB41qxCdHvy9FIDTpuTtPRKmcxsQ3UUBehR37moyiT4Ta089c3EkSjwnC1U9CYR4upRzLBqcXoZ4jAs1YBL8xYiccdfLY519K7Xurnwj5HblfoBybZ7xizzTU3a__8ynW02oFM3ItesYHmbLWJlqPs5OcWenwph8QjftKujXjIicHX4pOoSu_PCdcOXwwvexTHHcoGX_V7eOITVznBugLcBNZ7lJ3A0xoPesMBLqun0pRBu2cbPdxc31_ekk5ngRSZklNiVK4Tk6ZJwXPLQLksTWyam4wpEVhwzmnKCy2sACnSjAKn2uM6X0kZENRJtoMWqrqyewhTS5WWWrPM5Jxy52tUAwUTNoXMaMn3EZ7Zbez9OAwndGXr92b8bbl9tBttP36N922MWatVmyQHf798iFZi05cSRo_QovP_sD1GS8XHtGwmJ61_-Gd_cPcFL_rEvg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miR-182-mediated+downregulation+of+BRCA1+impacts+DNA+repair+and+sensitivity+to+PARP+inhibitors&rft.jtitle=Molecular+cell&rft.au=Moskwa%2C+Patryk&rft.au=Buffa%2C+Francesca+M&rft.au=Pan%2C+Yunfeng&rft.au=Panchakshari%2C+Rohit&rft.date=2011-01-21&rft.issn=1097-4164&rft.eissn=1097-4164&rft.volume=41&rft.issue=2&rft.spage=210&rft_id=info:doi/10.1016%2Fj.molcel.2010.12.005&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1097-4164&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1097-4164&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1097-4164&client=summon